Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Seminal Vesicle	NCIT_C12787	[One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus deferens to form the ejaculatory duct.]
Seminiferous Epithelium	NCIT_C49296
Stratified Epithelium	NCIT_C33622
Seminiferous Tubule	NCIT_C13047	[A hollow tube located in the testes, which is the site of germination, maturation, and transportation of the sperm cells in a sexually mature male.]
Small Intestinal Lamina Propria	NCIT_C49297
Small Intestinal Mucosa	NCIT_C33568	[Mucosa arranged into two fundamental structures - villi and crypts of Lieberkuhn. Villi are projections into the lumen of the small intestine, covered with simple columnar epithelium. Crypts of Lieberkuhn are moat-like invaginations of the epithelium around the villi that extend through the lamina propria down to the muscularis mucosae. Lymphocytes often invade the epithelium or form solitary lymphoid nodules in the lamina propria. Lymph nodules may form longitudinal aggregations of 30-50 nodules in the lamina propria of the ileum. These large aggregations are called Peyer's patches. The muscularis mucosae has two layers and extends into the intestinal villi, where the smooth muscle cells form a longitudinal bundle in the centre of the villi. The small intestinal mucosa secretes gastrin, somatostatin, cholecystokinin and secretin.]
Recombinant DNA-L523S Vaccine	NCIT_C49290	[A plasmid DNA encoding human L523S, an RNA-binding protein that belongs to the KOC (K homology domain containing protein overexpressed in cancer) family, with potential antineoplastic activity. Vaccination with L523S DNA may stimulate a cytotoxic T lymphocytes (CTL) response against tumor cells that express the L523S protein. As an oncofetal protein, L523S is normally expressed in early embryonic tissue, but is overexpressed in certain cancer cell types.]
Principal Component Analysis	NCIT_C49291	[A vector space transform used to reduce the dimensionality in a dataset while retaining those characteristics of the dataset that contribute most to its variance.]
County	NCIT_C49292	[A region created by territorial division for the purpose of local government.]
Stage I Lung Cancer AJCC v7	NCIT_C88888	[Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0). T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension. N0: No regional lymph metastasis. M0: No distant metastasis. (AJCC 7th ed.)]
Lung Cancer by AJCC v7 Stage	NCIT_C91232	[A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 7th edition.]
Stage II Lung Cancer AJCC v7	NCIT_C88889	[Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0). T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension. T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension. T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis. N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)]
Lung Cancer cM0 TNM Finding v7	NCIT_C88884	[Lung cancer without evidence of distant metastasis. (from AJCC 7th Ed.)]
Lung Cancer Clinical Distant Metastasis TNM Finding v7	NCIT_C88883	[A clinical finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.]
Lung Cancer cM1 TNM Finding v7	NCIT_C88885	[Lung cancer with distant metastasis. (from AJCC 7th Ed.)]
Lung Cancer cM1a TNM Finding v7	NCIT_C88886	[Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion. Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple cytopathologic examinations of pleural (or pericardial) fluid) are negative for tumor, and the fluid is nonbloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be classified as M0. (from AJCC 7th Ed.)]
Lung Cancer cM1b TNM Finding v7	NCIT_C88887	[Distant metastasis. (from AJCC 7th Ed.)]
Brovanexine	NCIT_C74261
Ambroxol	NCIT_C74262
Expectorant	NCIT_C29767	[Any agent that promotes ejection of mucus or exudate from the lungs, bronchi and trachea by decreasing mucus viscosity or by increasing the secretion of mucus in a dry, unproductive cough.]